Ocular immunology and inflammation · 2026
T Cells Show an Immune Response Against Epstein-Barr Virus Nuclear Antigen 1 (EBNA-1) in Paediatric Autoimmune Uveitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hendrikse Jytte, de Ligt Aafke M, Wennink Roos A W, de Boer Joke H, Kuiper Jonas J W
Аннотация
PURPOSE: The purpose of this study was to examine the reactivity of T cells from children with paediatric uveitis to the complete Epstein-Barr virus (EBV) EBNA-1 antigen and to the EBNA-1 AA 397-408 epitope in relation to the class II HLA-DRB1*15:01 genetic profile.
METHODS: We used ELISPOT to measure the IFN-γ T cell response of eleven patients with paediatric non-infectious uveitis and three control patients to a peptide pool containing the complete EBV EBNA-1 antigen and to the EBV EBNA-1 AA 397-408 peptide motif. Next-generation sequencing data or, when unavailable, TaqMan assay was used to categorize patients based on HLA-DRB1*15:01 profile.
RESULT: Overall, 9/11 (81.8%) of uveitis patients had a positive T cell response against the EBV EBNA-1 pool. Of the five HLA-DRB1*15:01 positive uveitis and control patients, four (80%) had a positive T cell response to the EBV EBNA-1 pool. No statistically significant differences were seen in number of spot forming units per 106 cells against the EBV EBNA-1 pool between HLA-DRB1*15:01 positive compared to HLA-DRB1*15:01 negative uveitis patients. One patient with intermediate uveitis who was homozygous positive for HLA-DRB1*15:01 had a positive T cell response to the EBNA-1 AA 397-408 peptide motif condition.
CONCLUSION: In this exploratory study, we found that the majority of uveitis patients, regardless of HLA-DRB1*15:01 genetic background, had a measurable T cell response against the complete EBV EBNA-1 antigen. A positive T cell response against the EBNA-1 AA 397-408 epitope specifically was measured in one uveitis patient; a homozygote HLA-DRB1*15:01 positive patient with intermediate uveitis.
METHODS: We used ELISPOT to measure the IFN-γ T cell response of eleven patients with paediatric non-infectious uveitis and three control patients to a peptide pool containing the complete EBV EBNA-1 antigen and to the EBV EBNA-1 AA 397-408 peptide motif. Next-generation sequencing data or, when unavailable, TaqMan assay was used to categorize patients based on HLA-DRB1*15:01 profile.
RESULT: Overall, 9/11 (81.8%) of uveitis patients had a positive T cell response against the EBV EBNA-1 pool. Of the five HLA-DRB1*15:01 positive uveitis and control patients, four (80%) had a positive T cell response to the EBV EBNA-1 pool. No statistically significant differences were seen in number of spot forming units per 106 cells against the EBV EBNA-1 pool between HLA-DRB1*15:01 positive compared to HLA-DRB1*15:01 negative uveitis patients. One patient with intermediate uveitis who was homozygous positive for HLA-DRB1*15:01 had a positive T cell response to the EBNA-1 AA 397-408 peptide motif condition.
CONCLUSION: In this exploratory study, we found that the majority of uveitis patients, regardless of HLA-DRB1*15:01 genetic background, had a measurable T cell response against the complete EBV EBNA-1 antigen. A positive T cell response against the EBNA-1 AA 397-408 epitope specifically was measured in one uveitis patient; a homozygote HLA-DRB1*15:01 positive patient with intermediate uveitis.